Colorectal CancerCHASENCT04461275
CHASE : aCcelerated 23-Hour erAS Care for Colorectal Surgery
A study testing ERAS 2.0 in people with Colorectal Cancer and Enhanced Recovery After Surgery, run by Zuyderland Medisch Centrum at 1 site in Netherlands.
Trial summary
Rationale: Throughout the years, there has been a rapid change in the perioperative protocols and procedures surrounding colorectal surgery. Upon the introduction of the Enhanced Recovery After Surgery (ERAS) program in Western countries, an improvement in postoperative outcomes was seen. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Colorectal Cancer, Enhanced Recovery After Surgery
- What is being tested?
- ERAS 2.0
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 41 participants
- Where
- 1 siteNetherlands
- Study dates
- 19 Jun 2020to 30 Sep 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent;
- Is ≥ 18 years ≤ 80;
- BMI ≤ 35 kg/m2;
- WHO performance status = 0
- Is diagnosed with (non-complicated) colorectal cancer
- Is scheduled to undergo elective laparoscopic colorectal surgery (ileocecal resection, right or left hemicolectomy, transvers colon resection) with primary anastomosis;
Show all 10Show fewer
- Primary anastomosis is performed intracorporeally;
- Uncomplicated operation;
- Readily available ambulant care provided by an adult family member for the first 24 hours after discharge;
- Patient is adequately reachable by phone.
Who cannot join
- ASA classification ≥ 3;
- Subjects who have limited mobility and/or need to be aided/assisted when mobilizing;
- Subjects with a history of active pulmonary infection, any other active infection, any uncontrolled medical disease
- Subjects with a contraindication for oral NSAIDs;
- Subjects with a contraindication for spinal anesthesia;
- Subjects requiring parenteral nutrition prior to surgery;
Show all 10Show fewer
- Subjects scheduled to undergo lower rectal resections;
- Subjects receiving an ostomy;
- Subjects who experience complications preoperatively;
- Subjects who are mentally incompetent, challenged or requiring aid with daily life activities.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: ERAS 2.0 - Accelerated 23-hour ERAS Care for Colorectal Surgery
Rationale: Throughout the years, there has been a rapid change in the perioperative protocols and procedures surrounding colorectal surgery. Upon the introduction of the Enhanced Recovery After Surgery (ERAS) program in Western countries, an improvement in postoperative outcomes was seen. Nowadays, researchers focus on further improving the current standard ERAS programs enabling an accelerated version hereof.
Objective: The aim of this study is to investigate the feasibility and safety of a 23-hour accelerated ERAS protocol (ERAS 2.0) for patients undergoing colorectal surgery compared to a retrospective cohort of patients who followed ERAS 1.0 for colorectal surgery. In this ERAS 2.0 protocol, patients undergoing colorectal surgery will be discharged within 23 hours after surgery.
Read more
Study design: This study is an investigator-initiated, single-center prospective study.
Study population: Patients aged ≥ 18 years ≤ 80 undergoing surgical resection for colorectal pathology that meet the eligibility criteria will be invited to participate in this study.
Intervention: Adhering to a strict multidisciplinary and multifaceted ERAS 2.0 protocol, patients receiving elective colorectal surgery will be discharged 23-hours after surgery.
Main study parameters/endpoints: Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery. Success rate will be measured in readmission rate and safety will be measured with rate of serious adverse events (Clavien Dindo ≥3b). Success rate (feasibility) will also be measured in percentage of patients who were not able to be discharged 23 hours after surgery.
Read the detailed description
The aim of this study is to investigate the feasibility and safety of a 23-hour accelerated ERAS 2.0 protocol for patients undergoing colorectal surgery compared to a retrospective cohort of patients who followed ERAS 1.0 for colorectal surgery. In this ERAS 2.0 protocol, patients undergoing colorectal surgery will be discharged within 23 hours after surgery.
Primary Objective:
To assess the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing colorectal surgery.
Secondary Objective(s):
- Postoperative outcomes, including morbidity and mortality within 30 days;
- Patient experience and satisfaction.
This study is an investigator-initiated, single-center prospective feasibility study. This feasibility study will compare 30 consecutive patients following the ERAS 2.0 program to 30 patients of a retrospective cohort who followed the current standard ERAS 1.0 protocol in Zuyderland Medical Center.
Population:
Patients diagnosed with malignant colorectal disease which requires surgical resection that meets the eligibility criteria will be invited to participate in this feasibility study. Patients will be approached on the surgical outpatient clinic at both locations from Zuyderland Medical Center. The study and actual surgery will take place only at location Sittard-Geleen.
Screening:
After written informed consent is obtained, participants are screened for further suitability. All participants will undergo a brief physical screening performed by an anesthesiologist. This screening will include: a complete cardiopulmonary physical examination, rest-EKG and routine laboratory workup. Should any contraindications be found during this screening, this will be used to further exclude patients from this study. In addition, participants are given extra information about ERAS 2.0 and expectations will be managed by discussing common side-effects and symptoms after general anesthesia and laparoscopic colorectal surgery.Only participants scheduled to undergo left-sided colorectal surgery are given a prescription for Bisacodyl 5mg as bowel preparation. Patients will be instructed to take 2 tablets the night before surgery and one tablet the morning of the surgery. Non-diabetic participants will be provided with 2 preoperative carbohydrate drinks (PreOp).
6.2.2 Preoperative Surgical ward On the day of surgery, participants are admitted early on the surgical ward and are prepared for surgery. They are required to present themselves at the surgical ward two hours prior to surgery. Participants will then be instructed to take the second preoperative carbohydrate drink (PreOp). Diabetic participants will not be provided with PreOp. As part of ERAS 2.0, it will be required of the participants to walk to the Holding with their bed with the assistance of their nurse.
Pre Anesthesia Care Unit (PACU) While participants are being prepared for anesthesia and surgery, they will once more be informed about the possible side-effects and discomfort associated with anesthesia and abdominal surgery. This in an effort to further manage expectations.
Preoperative administration of multimodal analgesia regimen is initiated in the PACU. This will consist of 1 gram Paracetamol and 600 milligrams Gabapentin (300 mg if GFR <60 ml/min or age> 70 years) intravenously.
Perioperative Participants are brought to the operating theater and the "time-out" check will be done. Here after the participant is prepared for anesthesia and surgery. Standard monitoring according to ASA guidelines will be applied.
Anesthesia Pre-induction: Spinal anesthesia consisting of 12.5 mg Bupivacaine combined with intrathecal morphine 300 mcg will be administered intravenously.
Induction: 1-2 mg per kg Propofol 2% plus TIVA (a mix of 50ml propofol plus 2% 500mcg Ultiva) at 4mcg/ml. In addition a bolus of Ketanest-S will be administered at 0.25 mg/kg. Dosages are adjusted to age and weight of the participant.
Fluid therapy: only balanced crystalloids are chosen for intravenous fluids (Ringer Lactate or Stereofundin). Optimization of fluid therapy is achieved by guided Esophageal Doppler or Flo Trac System management up until the end of surgery. Continuous perfusion of Ringer Lactate / Stereofundin will be set at 3 ml/kg/hour IV.
Ventilation: Optimal ventilation parameters will be obtained during surgery with: Total Volume 6-8 ml/kg; minimum FiO2 to prevent atelectasis and optimal PEEP (patients specific) to prevent peri- and postoperative atelectasis.
Surgery - peroperative All participants will be operated on laparoscopically, in a true minimally invasive manner. With exception of the following two factors pertaining to ERAS 2.0, all operations will be performed according to standard hospital protocols. (1) Starting intra-abdominal pressure will be set at 12 mmHg. During surgery, the intra-abdominal pressure will be gradually reduced to an end pressure of 8 mmHg. This method has been proven to be safe and is associated with less postoperative pain caused by laparoscopic insufflation. (2) Primary anastomosis will be performed intracorporeally as this method is associated with similar results to extracorporeal anastomosis. No additional mini-laparotomy will be performed. The specimen will be extracted through a suprapubic pfannenstiel incision. After surgery, routine postoperative measures will be used to omit sedation and commence recovery. If surgery was uncomplicated and performed under 2 hours, the urinary catheter will be removed in the operation theater.
Postoperative Recovery ward After surgery, participants are brought to the recovery ward where further care will be given before transporting them to the surgical ward. Here participants are continuously monitored and checked for postoperative nausea, pain and discomfort. In case of nausea and/or vomiting, participants are treated according to standard hospital protocols. To bridge postoperative pain management, participants will receive 7.5mg Meloxicam postoperatively. Postoperative pain management consists of 1000mg Paracetamol IV every 6 hours. If necessary, 5-20mg Oxynorm (tablet) can be offered up to 6 times a day. To stimulate intake and gastrointestinal motility, patients are offered a popsicle on the recovery ward.
Surgical ward
Postoperative day 0:
Upon arrival on the surgical ward, postoperative care is resumed according to standard hospital protocol with respect to anti-emetic care, patient monitoring and thromboprophylaxis. Routine physical examination and evaluation will take place.
The postoperative care-points of ERAS 2.0 are: Minimal-opiate pain management; early removal of the urinary catheter, early oral intake; early stop of IV-fluids and early mobilization. Pain management is achieved with Paracetamol and Meloxicam, and if needed Oxynorm. Standard hospital dosages will be used. At 22:00 hours, if still in situ, urinary catheters will be removed. Intake is stimulated and participants will be offered food and beverages, starting with fluids gradually increasing to full oral intake tolerance of their normal diet. Participants are encouraged to sit up straight in bed as much as possible and to mobilize in their room.
Postoperative day 1:
The following day, participants will be evaluated for measure of recovery and suitability for discharge. Routine physical examination and evaluation will take place. The surgical incision sites will be evaluated and the abdomen will be examined for swelling, redness and for possible hematoma/bleeds. Participants will be evaluated for pain using the VAS pain score and will be evaluated for other signs of discomfort.
Participants are considered as ' functionally recovered' and safe for discharge if the following criteria are met:
- Pain under control with oral analgesics (VAS <4)
- No symptoms of nausea and/or vomiting
- Flatus or passing of stools
- Oral intake possible (resumed full diet)
- Spontaneous micturition
- Able to mobilize independently
- No alarm signs present (fever, tachycardia, hypotension, dyspnea or somnolence).
Participants are only discharged if they tick off all the requirements on the discharge checklist. Before discharge, their nurse will explain the recovery trajectory after discharge, including the telephonic aftercare. This includes pain management, dietary and mobilizing advice, thromboprophylaxis instructions and alarm symptoms to be weary of. Participants will receive a discharge folder with all necessary information, including all available contact numbers. The abovementioned information will be included in the discharge letter that patients receive upon leaving the surgical ward.
Care after discharge Telephonic aftercare On the evening of the day of discharge, participants will be contacted by the attending nurse. A premade ERAS 2.0 checklist concerning recovery and possible alarm symptoms will be used to assess recovery. On postoperative day 4, participants will be contacted again via telephone by the attending nurse practitioner, and the same steps are repeated.
Outpatient clinic Participants are given an appointment with a colorectal surgeon to be checked at the surgical outpatient clinic. During this appointment, the overall experience of the participant will be evaluated, together with his/her clinical recovery. The participant will be provided with an evaluation form.
- Conditions
- Colorectal Cancer, Enhanced Recovery After Surgery
- Being tested
- ERAS 2.0
- Keywords
- Colorectal Cancer, Enhanced Recovery After Surgery, Accelerated Care, Truly Minimally Invasive Surgery
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ERAS 2.0Other
ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
| Study group | Role | What they receive |
|---|---|---|
| ERAS 2.0 group | Experimental | Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol. Receives: Other: ERAS 2.0 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.
Success rate (feasibility) will be measured in readmission rate and safety will be measured with rate of serious adverse events (Clavien Dindo ≥3b).
Measured: 30 days
Secondary outcomes (3)
• Number of Participants who develop Postoperative Complications within 30 days
- Number of Participants who develop Postoperative Complications within 30 days
Measured: 30 day
• Number of Participants with Postoperative Mortality within 30 days
- Number of Participants with Postoperative Mortality within 30 days
Measured: 30 days
• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.
- Patient satisfaction evaluation questionnaire to evaluate the patients subjective experience during the duration of this study and their subjective experience with the ERAS 2.0 protocol. In this questionnaire, patients will be asked to evaluate their experience based on 5 pre-set questions with a 10-point scale (1 being very bad and 10 being very good).
- Were you sufficiently informed about the ERAS 2.0 protocol?
- How did you experience the guidance provided (by nurses and doctors) within this protocol?
- Was the care provided after hospital discharge satisfactory?
- Was it necessary to contact the hospital after discharge? And if yes, how often?
- What grade would you give this programme?
Measured: 10 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2020
- Study start19 Jun 2020
- Primary completion30 Aug 2021
- Study completion30 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This study is an investigator-initiated, single-center prospective feasibility study. This feasibility study will compare 30 consecutive patients following the ERAS 2.0 program to 30 patients of a retrospective cohort who followed the current standard ERAS 1.0 protocol.
- Masking
- None (open label)
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zuyderland Medisch Centrum
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- James van Bastelaar, M.D., PhD, Principal investigator, GE-, Oncologic-surgeon
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04461275
- Sponsor's protocol ID
- Z20202017
- Acronym
- CHASE
- Status last verified
- Mar 2022
- First submitted
- 25 Jun 2020
- Last updated
- 2 Mar 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Al-Mazrou AM, Chiuzan C, Kiran RP. Factors influencing discharge disposition after colectomy. Surg Endosc. 2018 Jul;32(7):3032-3040. doi: 10.1007/s00464-017-6013-z. Epub 2017 Dec 27.
PubMed 29282575Dobradin A, Ganji M, Alam SE, Kar PM. Laparoscopic colon resections with discharge less than 24 hours. JSLS. 2013 Apr-Jun;17(2):198-203. doi: 10.4293/108680813X13654754535791.
PubMed 23925012Chand M, De'Ath HD, Rasheed S, Mehta C, Bromilow J, Qureshi T. The influence of peri-operative factors for accelerated discharge following laparoscopic colorectal surgery when combined with an enhanced recovery after surgery (ERAS) pathway. Int J Surg. 2016 Jan;25:59-63. doi: 10.1016/j.ijsu.2015.11.047. Epub 2015 Nov 30.
PubMed 26654893Rossi G, Vaccarezza H, Vaccaro CA, Mentz RE, Im V, Alvarez A, Quintana GO. Two-day hospital stay after laparoscopic colorectal surgery under an enhanced recovery after surgery (ERAS) pathway. World J Surg. 2013 Oct;37(10):2483-9. doi: 10.1007/s00268-013-2155-x.
PubMed 23881088Emmanuel A, Chohda E, Botfield C, Ellul J. Accelerated discharge within 72 hours of colorectal cancer resection using simple discharge criteria. Ann R Coll Surg Engl. 2018 Jan;100(1):52-56. doi: 10.1308/rcsann.2017.0149. Epub 2017 Sep 15.
PubMed 29022790Levy BF, Scott MJ, Fawcett WJ, Rockall TA. 23-hour-stay laparoscopic colectomy. Dis Colon Rectum. 2009 Jul;52(7):1239-43. doi: 10.1007/DCR.0b013e3181a0b32d.
PubMed 19571699
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ERAS 2.0 - Accelerated 23-hour ERAS Care for Colorectal Surgery
- ClinicalTrials.gov ID
- NCT04461275
- Acronym / sponsor ID
- CHASE / Z20202017
- Conditions
- Colorectal Cancer, Enhanced Recovery After Surgery
- Keywords
- Colorectal Cancer, Enhanced Recovery After Surgery, Accelerated Care, Truly Minimally Invasive Surgery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- Zuyderland Medisch CentrumUniversity, hospital or other
- Study start
- 19 Jun 2020 (actual)
- Primary completion
- 30 Aug 2021 (actual)
- Study completion
- 30 Sep 2021 (actual)
- First posted
- 8 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Throughout the years, there has been a rapid change in the perioperative protocols and procedures surrounding colorectal surgery. Upon the introduction of the Enhanced Recovery After Surgery (ERAS) program in Western countries, an improvement in postoperative outcomes was seen. Nowadays, researchers focus on further improving the current standard ERAS programs enabling an accelerated version hereof.
Objective: The aim of this study is to investigate the feasibility and safety of a 23-hour accelerated ERAS protocol (ERAS 2.0) for patients undergoing colorectal surgery compared to a retrospective cohort of patients who followed ERAS 1.0 for colorectal surgery. In this ERAS 2.0 protocol, patients undergoing colorectal surgery will be discharged within 23 hours after surgery.
Study design: This study is an investigator-initiated, single-center prospective study.
Study population: Patients aged ≥ 18 years ≤ 80 undergoing surgical resection for colorectal pathology that meet the eligibility criteria will be invited to participate in this study.
Intervention: Adhering to a strict multidisciplinary and multifaceted ERAS 2.0 protocol, patients receiving elective colorectal surgery will be discharged 23-hours after surgery.
Main study parameters/endpoints: Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery. Success rate will be measured in readmission rate and safety will be measured with rate of serious adverse events (Clavien Dindo ≥3b). Success rate (feasibility) will also be measured in percentage of patients who were not able to be discharged 23 hours after surgery.
Detailed description
The aim of this study is to investigate the feasibility and safety of a 23-hour accelerated ERAS 2.0 protocol for patients undergoing colorectal surgery compared to a retrospective cohort of patients who followed ERAS 1.0 for colorectal surgery. In this ERAS 2.0 protocol, patients undergoing colorectal surgery will be discharged within 23 hours after surgery.
Primary Objective:
To assess the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing colorectal surgery.
Secondary Objective(s):
- Postoperative outcomes, including morbidity and mortality within 30 days;
- Patient experience and satisfaction.
This study is an investigator-initiated, single-center prospective feasibility study. This feasibility study will compare 30 consecutive patients following the ERAS 2.0 program to 30 patients of a retrospective cohort who followed the current standard ERAS 1.0 protocol in Zuyderland Medical Center.
Population:
Patients diagnosed with malignant colorectal disease which requires surgical resection that meets the eligibility criteria will be invited to participate in this feasibility study. Patients will be approached on the surgical outpatient clinic at both locations from Zuyderland Medical Center. The study and actual surgery will take place only at location Sittard-Geleen.
Screening:
After written informed consent is obtained, participants are screened for further suitability. All participants will undergo a brief physical screening performed by an anesthesiologist. This screening will include: a complete cardiopulmonary physical examination, rest-EKG and routine laboratory workup. Should any contraindications be found during this screening, this will be used to further exclude patients from this study. In addition, participants are given extra information about ERAS 2.0 and expectations will be managed by discussing common side-effects and symptoms after general anesthesia and laparoscopic colorectal surgery.Only participants scheduled to undergo left-sided colorectal surgery are given a prescription for Bisacodyl 5mg as bowel preparation. Patients will be instructed to take 2 tablets the night before surgery and one tablet the morning of the surgery. Non-diabetic participants will be provided with 2 preoperative carbohydrate drinks (PreOp).
6.2.2 Preoperative Surgical ward On the day of surgery, participants are admitted early on the surgical ward and are prepared for surgery. They are required to present themselves at the surgical ward two hours prior to surgery. Participants will then be instructed to take the second preoperative carbohydrate drink (PreOp). Diabetic participants will not be provided with PreOp. As part of ERAS 2.0, it will be required of the participants to walk to the Holding with their bed with the assistance of their nurse.
Pre Anesthesia Care Unit (PACU) While participants are being prepared for anesthesia and surgery, they will once more be informed about the possible side-effects and discomfort associated with anesthesia and abdominal surgery. This in an effort to further manage expectations.
Preoperative administration of multimodal analgesia regimen is initiated in the PACU. This will consist of 1 gram Paracetamol and 600 milligrams Gabapentin (300 mg if GFR <60 ml/min or age> 70 years) intravenously.
Perioperative Participants are brought to the operating theater and the "time-out" check will be done. Here after the participant is prepared for anesthesia and surgery. Standard monitoring according to ASA guidelines will be applied.
Anesthesia Pre-induction: Spinal anesthesia consisting of 12.5 mg Bupivacaine combined with intrathecal morphine 300 mcg will be administered intravenously.
Induction: 1-2 mg per kg Propofol 2% plus TIVA (a mix of 50ml propofol plus 2% 500mcg Ultiva) at 4mcg/ml. In addition a bolus of Ketanest-S will be administered at 0.25 mg/kg. Dosages are adjusted to age and weight of the participant.
Fluid therapy: only balanced crystalloids are chosen for intravenous fluids (Ringer Lactate or Stereofundin). Optimization of fluid therapy is achieved by guided Esophageal Doppler or Flo Trac System management up until the end of surgery. Continuous perfusion of Ringer Lactate / Stereofundin will be set at 3 ml/kg/hour IV.
Ventilation: Optimal ventilation parameters will be obtained during surgery with: Total Volume 6-8 ml/kg; minimum FiO2 to prevent atelectasis and optimal PEEP (patients specific) to prevent peri- and postoperative atelectasis.
Surgery - peroperative All participants will be operated on laparoscopically, in a true minimally invasive manner. With exception of the following two factors pertaining to ERAS 2.0, all operations will be performed according to standard hospital protocols. (1) Starting intra-abdominal pressure will be set at 12 mmHg. During surgery, the intra-abdominal pressure will be gradually reduced to an end pressure of 8 mmHg. This method has been proven to be safe and is associated with less postoperative pain caused by laparoscopic insufflation. (2) Primary anastomosis will be performed intracorporeally as this method is associated with similar results to extracorporeal anastomosis. No additional mini-laparotomy will be performed. The specimen will be extracted through a suprapubic pfannenstiel incision. After surgery, routine postoperative measures will be used to omit sedation and commence recovery. If surgery was uncomplicated and performed under 2 hours, the urinary catheter will be removed in the operation theater.
Postoperative Recovery ward After surgery, participants are brought to the recovery ward where further care will be given before transporting them to the surgical ward. Here participants are continuously monitored and checked for postoperative nausea, pain and discomfort. In case of nausea and/or vomiting, participants are treated according to standard hospital protocols. To bridge postoperative pain management, participants will receive 7.5mg Meloxicam postoperatively. Postoperative pain management consists of 1000mg Paracetamol IV every 6 hours. If necessary, 5-20mg Oxynorm (tablet) can be offered up to 6 times a day. To stimulate intake and gastrointestinal motility, patients are offered a popsicle on the recovery ward.
Surgical ward
Postoperative day 0:
Upon arrival on the surgical ward, postoperative care is resumed according to standard hospital protocol with respect to anti-emetic care, patient monitoring and thromboprophylaxis. Routine physical examination and evaluation will take place.
The postoperative care-points of ERAS 2.0 are: Minimal-opiate pain management; early removal of the urinary catheter, early oral intake; early stop of IV-fluids and early mobilization. Pain management is achieved with Paracetamol and Meloxicam, and if needed Oxynorm. Standard hospital dosages will be used. At 22:00 hours, if still in situ, urinary catheters will be removed. Intake is stimulated and participants will be offered food and beverages, starting with fluids gradually increasing to full oral intake tolerance of their normal diet. Participants are encouraged to sit up straight in bed as much as possible and to mobilize in their room.
Postoperative day 1:
The following day, participants will be evaluated for measure of recovery and suitability for discharge. Routine physical examination and evaluation will take place. The surgical incision sites will be evaluated and the abdomen will be examined for swelling, redness and for possible hematoma/bleeds. Participants will be evaluated for pain using the VAS pain score and will be evaluated for other signs of discomfort.
Participants are considered as ' functionally recovered' and safe for discharge if the following criteria are met:
- Pain under control with oral analgesics (VAS <4)
- No symptoms of nausea and/or vomiting
- Flatus or passing of stools
- Oral intake possible (resumed full diet)
- Spontaneous micturition
- Able to mobilize independently
- No alarm signs present (fever, tachycardia, hypotension, dyspnea or somnolence).
Participants are only discharged if they tick off all the requirements on the discharge checklist. Before discharge, their nurse will explain the recovery trajectory after discharge, including the telephonic aftercare. This includes pain management, dietary and mobilizing advice, thromboprophylaxis instructions and alarm symptoms to be weary of. Participants will receive a discharge folder with all necessary information, including all available contact numbers. The abovementioned information will be included in the discharge letter that patients receive upon leaving the surgical ward.
Care after discharge Telephonic aftercare On the evening of the day of discharge, participants will be contacted by the attending nurse. A premade ERAS 2.0 checklist concerning recovery and possible alarm symptoms will be used to assess recovery. On postoperative day 4, participants will be contacted again via telephone by the attending nurse practitioner, and the same steps are repeated.
Outpatient clinic Participants are given an appointment with a colorectal surgeon to be checked at the surgical outpatient clinic. During this appointment, the overall experience of the participant will be evaluated, together with his/her clinical recovery. The participant will be provided with an evaluation form.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This study is an investigator-initiated, single-center prospective feasibility study. This feasibility study will compare 30 consecutive patients following the ERAS 2.0 program to 30 patients of a retrospective cohort who followed the current standard ERAS 1.0 protocol.
| Arm | Type | Receives |
|---|---|---|
| ERAS 2.0 group | Experimental | Other: ERAS 2.0Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Signed informed consent;
- Is ≥ 18 years ≤ 80;
- BMI ≤ 35 kg/m2;
- WHO performance status = 0
- Is diagnosed with (non-complicated) colorectal cancer
Key exclusion criteria (10 listed)
- ASA classification ≥ 3;
- Subjects who have limited mobility and/or need to be aided/assisted when mobilizing;
- Subjects with a history of active pulmonary infection, any other active infection, any uncontrolled medical disease
- Subjects with a contraindication for oral NSAIDs;
- Subjects with a contraindication for spinal anesthesia;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ERAS 2.0ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis) | Other | ERAS 2.0 group |
Primary outcome
Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.
Time frame: 30 days
Success rate (feasibility) will be measured in readmission rate and safety will be measured with rate of serious adverse events (Clavien Dindo ≥3b).
3 secondary outcomes
• Number of Participants who develop Postoperative Complications within 30 days
Time frame: 30 day
• Number of Participants with Postoperative Mortality within 30 days
Time frame: 30 days
• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.
Time frame: 10 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2022.
- Background: PubMed 29282575Al-Mazrou AM, Chiuzan C, Kiran RP. Factors influencing discharge disposition after colectomy. Surg Endosc. 2018 Jul;32(7):3032-3040. doi: 10.1007/s00464-017-6013-z. Epub 2017 Dec 27.
- Background: PubMed 23925012Dobradin A, Ganji M, Alam SE, Kar PM. Laparoscopic colon resections with discharge less than 24 hours. JSLS. 2013 Apr-Jun;17(2):198-203. doi: 10.4293/108680813X13654754535791.
- Background: PubMed 26654893Chand M, De'Ath HD, Rasheed S, Mehta C, Bromilow J, Qureshi T. The influence of peri-operative factors for accelerated discharge following laparoscopic colorectal surgery when combined with an enhanced recovery after surgery (ERAS) pathway. Int J Surg. 2016 Jan;25:59-63. doi: 10.1016/j.ijsu.2015.11.047. Epub 2015 Nov 30.
- Results publication: PubMed 23881088Rossi G, Vaccarezza H, Vaccaro CA, Mentz RE, Im V, Alvarez A, Quintana GO. Two-day hospital stay after laparoscopic colorectal surgery under an enhanced recovery after surgery (ERAS) pathway. World J Surg. 2013 Oct;37(10):2483-9. doi: 10.1007/s00268-013-2155-x.
- Results publication: PubMed 29022790Emmanuel A, Chohda E, Botfield C, Ellul J. Accelerated discharge within 72 hours of colorectal cancer resection using simple discharge criteria. Ann R Coll Surg Engl. 2018 Jan;100(1):52-56. doi: 10.1308/rcsann.2017.0149. Epub 2017 Sep 15.
- Results publication: PubMed 19571699Levy BF, Scott MJ, Fawcett WJ, Rockall TA. 23-hour-stay laparoscopic colectomy. Dis Colon Rectum. 2009 Jul;52(7):1239-43. doi: 10.1007/DCR.0b013e3181a0b32d.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James van Bastelaar, M.D., PhD principal investigator
GE-, Oncologic-surgeon
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ERAS 2.0 in people with Colorectal Cancer and Enhanced Recovery After Surgery, run by Zuyderland Medisch Centrum at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery. (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04461275, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2022.